Introduction
Grepafloxacin is a new C5-methyl fluoroquinolone. It has increased antibacterial activity against Gram-positive bacteria, 1, 2 and intracellular organisms such as Chlamydia and Legionella spp., 3 when compared with ciprofloxacin and ofloxacin. Grepafloxacin achieves high concentrations in tissue, especially in the lung. 4 The in-vitro activity of grepafloxacin was determined for clinical and reference stains of different human Mycoplasma spp., and compared with that of the fluoroquinolones, sparfloxacin, ofloxacin and ciprofloxacin, and also two unrelated antimicrobials, doxycycline and erythromycin.
Materials and methods

Antimicrobials
Each of the following antimicrobial agents was provided by the manufacturer: grepafloxacin (GlaxoWellcome, Marly le Roi, France); sparfloxacin (Rhône-Poulenc-Rorer, Vitry-sur-Seine, France); ofloxacin and erythromycin (Roussel-Uclaf, Paris, France); ciprofloxacin (BayerPharma, Puteaux, France) and doxycycline (Pfizer, Orsay, France).
Susceptibility testing
MICs were determined as previously described, using an agar dilution method with Hayflick modified agar for mycoplasma strains, and a broth dilution method with Shepard medium for ureaplasma strains. 5 The final concentrations of antibiotics tested were 0.015-32 mg/L. Minimal bactericidal concentrations (MBCs) of grepafloxacin and of the comparative compounds were determined as previously reported, for a reference strain of each species in test tubes, containing Shepard broth medium for Ureaplasma urealyticum and Hayflick modified broth medium for the other mycoplasma species. 6 The MBC was the lowest antibiotic concentration inhibiting a colour change in the broth culture, within 4-10 days (according to the species). 
Strains
Results and discussion
Comparative in-vitro activities of grepafloxacin and other antimicrobials against all mycoplasma and ureaplasma strains, except M. hominis resistant mutants, are shown in the Table. The overall activity of grepafloxacin was very good against all strains tested. A concentration of 1 mg/L of grepafloxacin inhibited 90% of all strains, with the exception of the fluoroquinolone-resistant mutants of M. hominis PG21.
For M. pneumoniae and M. genitalium, MICs of grepafloxacin were comparable to those of sparfloxacin and doxycycline, but eight-to 16-fold lower than those of ofloxacin and ciprofloxacin. Erythromycin showed the best activity, inhibiting all M. pneumoniae and M. genitalium strains at a concentration р0.015 mg/L. M. hominis and M. fermentans were highly susceptible to grepafloxacin (MIC 90 0.06 mg/L and MIC range 0.03-0.12 mg/L, respectively) and sparfloxacin (MIC 90 0.03 mg/L and р0.015 mg/L, respectively). As expected, M. hominis and M. fermentans were resistant to erythromycin. Against M. penetrans, grepafloxacin was as active as sparfloxacin, but four-to eight-fold more active than ofloxacin and ciprofloxacin. The activity of grepafloxacin was also compared with that of sparfloxacin against the eight multistep fluoroquinoloneresistant mutants of the reference strain M. hominis PG21. A comparable increase in resistance to both antibiotics was found (MIC of grepafloxacin, 1-4 mg/L; MIC of sparfloxacin, 0.06-4 mg/L). It is noteworthy that none of the eight mutants showed increased MICs of erythromycin or doxycycline when compared with those for PG21.
As noted previously, 8 U. urealyticum was slightly less susceptible to grepafloxacin than it was to sparfloxacin, but overall grepafloxacin was four-fold more active than ofloxacin and ciprofloxacin. Doxycycline-resistant strains were as susceptible to grepafloxacin and sparfloxacin as doxycycline-susceptible strains (as previously described for other fluoroquinolones). 6, 8 For all Mycoplasma spp. (Table) , the MBCs of grepafloxacin were two-to 16-fold higher than the MICs. MBCs of sparfloxacin were lower by one dilution, except for M. genitalium. Ofloxacin and ciprofloxacin exhibited higher MBCs for mycoplasma strains than grepafloxacin or sparfloxacin. It should be noted that sparfloxacin MBCs were two-fold lower than those of grepafloxacin for all mycoplasma strains except M. genitalium. For the doxycycline-susceptible and -resistant strains of U. urealyticum, MBCs of grepafloxacin and sparfloxacin were bactericidal at only one dilution lower than MIC. These results indicate that grepafloxacin, like sparfloxacin, is bactericidal in vitro for all mycoplasmas and ureaplasmas.
In summary, grepafloxacin, like sparfloxacin 9 and BAY-128039, 6 can be ranked among the most active fluoroquinolones tested against Mycoplasma and Ureaplasma spp.; this study extends significantly the results of previous studies. 3, 8 Its reportedly high distribution in lung tissue 4 and demonstrated clinical efficacy in M. pneumoniae pneumonia 10 may ensure an important role for grepafloxacin in the treatment of respiratory infections caused by mycoplasma species. 
